Sanofi sheds Regeneron stake, but insists collaboration is u...

Sanofi and Regeneron’s once close relationship has been become a little more distant over the last couple of years, and the process continued this week after Sanofi said it wil

Sanofi CEO courts controversy after saying US is first in li...

Sanofi’s CEO Paul Hudson has courted controversy by saying the French pharma’s potential COVID-19 vaccine will likely be delivered to the US government first should it succeed in clinical t

Sanofi builds case for Sarclisa, challenging J&J’s Darzalex

Sanofi is trumpeting new data for its anti-CD38 drug Sarclisa as it tries to capture market share from Johnson & Johnson’s blockbuster Darzalex in the multiple myeloma mark

Sanofi and Regeneron eye challenge to Merck & Co in first li...

Sanofi and Regeneron could mount a challenge to Merck & Co’s Keytruda in untreated advanced lung cancer with their cancer immunotherapy latecomer Libtayo following new phase 3 results. 

Jury still out on IL-6 drugs in COVID-19 following prelimina...

There is a growing body of evidence that already-approved IL-6 could be used as treatments for COVID-19 following newly published clinical trial data – but the jury is out on whether they c

Sanofi links with Luminostics on smartphone coronavirus test